Novartis | NVS - Trade Creditors


Novartis reported $4.56B in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Amgen USD 20.89B 1.25B Dec/2025
AstraZeneca USD 25.28B 252M Dec/2025
Bausch Health Companies USD 600M 16M Dec/2025
Biogen USD 432M 18.9M Dec/2025
Bristol-Myers Squibb USD 4.29B 1.14B Sep/2025
Canopy Growth CAD 18.14M 5.94M Sep/2025
Corcept Therapeutics USD 34.45M 10.92M Sep/2025
Drreddys Laboratories INR 454.04M 854K Dec/2025
Eli Lilly USD 5.38B 1.12B Dec/2025
Gilead Sciences USD 808M 226M Sep/2025
GlaxoSmithKline GBP 15.38B 294M Dec/2025
Glaxosmithkline GBP 21.07B 7.42B Sep/2025
J&J USD 11.99B 2.37B Dec/2025
Merck USD 4.15B 102M Sep/2025
Novartis USD 4.56B 49M Sep/2025
Novartis USD 4.56B 49M Sep/2025
Pacira USD 17.69M 12.44M Sep/2025
Perrigo USD 469.7M 19.3M Sep/2025
Pfizer USD 5.02B 142M Sep/2025
Phibro Animal Health USD 133.3M 2.7M Dec/2025
Prestige Brands USD 42.95M 1.02M Dec/2025
Roche Holding CHF 5.78B 1.27B Dec/2025
Sanofi EUR 22.93B 927M Dec/2025
Sanofi EUR 22.93B 2.89B Dec/2025
Supernus Pharmaceuticals USD 108.61M 100.4M Sep/2025
Zoetis USD 487M 77M Dec/2025